Premium
Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia
Author(s) -
Ghanima Waleed,
Kahrs Johannes,
Dahl Tobias Gedde,
Tjonnfjord Geir E.
Publication year - 2004
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2004.00257.x
Subject(s) - imatinib mesylate , discontinuation , medicine , mesylate , imatinib , chronic myeloid leukaemia , anagrelide , complete response , myeloid leukemia , gastroenterology , chemotherapy , polycythemia vera , essential thrombocythemia , chemistry , organic chemistry
A 58‐yr‐old woman was diagnosed with Ph + chronic myeloid leukaemia in May 2001. She was initially treated with hydroxyurea and subsequently with interferon‐ α (IFN‐ α ). Imatinib mesylate was started in April 2002 after failure of IFN‐ α to induce a cytogenetic response. The patient remained on treatment with imatinib mesylate for 3 months during which she suffered daily fever resulting in discontinuation of the treatment. Response evaluation performed shortly after discontinuing imatinib mesylate revealed a complete cytogenetic remission and a substantial molecular response. Fifteen months later, she was still enjoying a major cytogenetic response. This case illustrates that a short course of imatinib mesylate may result in a sustained haematological and cytogenetic response.